A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: 5-Fluorouracil|DRUG: Carboplatin|DRUG: Cyclophosphamide|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Epirubicin|DRUG: Paclitaxel|DRUG: Pertuzumab|DRUG: Placebo|DRUG: Trastuzumab
Sponsor: Hoffmann-La Roche
Collaborators: Genentech, Inc.|Breast International Group